Bengt Simonsson

Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Hehlmann, Ruediger; Cortes, Jorge E.; Zyczynski, Teresa; Gambacorti-Passerini, Carlo et al.

Part of American Journal of Hematology, p. 46-54, 2019

• DOI for Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY
• Download full text (pdf) of Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

Hoffmann, V S; Baccarani, M; Hasford, J; Castagnetti, F et al.

Part of Leukemia, p. 593-601, 2017

• DOI for Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

PATRONES DE CAMBIO DE LOS INHIBIDORES DE LA TIROSINA CINASA BCR-ABL1 EN PACIENTES CON LMC EN FASE CRÓNICA EN LA PRÁCTICA CLÍNICA RUTINARIA ESTUDIO SIMPLICITY

Perez Encinas, M.; Goldberg, S. L.; Michallet, M.; Hehlmann, R. et al.

Part of Haematologica, p. 285-285, 2017

First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Goldberg, Stuart L.; Cortes, Jorge E.; Gambacorti-Passerini, Carlo; Hehlmann, Ruediger et al.

Part of American Journal of Hematology, p. 1214-1223, 2017

• DOI for First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY
• Download full text (pdf) of First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

Söderlund, Stina; Christiansson, Lisa; Persson, Inger; Hjorth-Hansen, Henrik et al.

Part of Leukemia Research, p. 95-103, 2016

• DOI for Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Hehlmann, Ruediger; Cortes, Jorge E.; Zyczynski, Teresa; Gambacorti-Passerini, Carlo et al.

Part of American Journal of Hematology, p. 46-54, 2019

• DOI for Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY
• Download full text (pdf) of Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

Hoffmann, V S; Baccarani, M; Hasford, J; Castagnetti, F et al.

Part of Leukemia, p. 593-601, 2017

• DOI for Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

PATRONES DE CAMBIO DE LOS INHIBIDORES DE LA TIROSINA CINASA BCR-ABL1 EN PACIENTES CON LMC EN FASE CRÓNICA EN LA PRÁCTICA CLÍNICA RUTINARIA ESTUDIO SIMPLICITY

Perez Encinas, M.; Goldberg, S. L.; Michallet, M.; Hehlmann, R. et al.

Part of Haematologica, p. 285-285, 2017

First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Goldberg, Stuart L.; Cortes, Jorge E.; Gambacorti-Passerini, Carlo; Hehlmann, Ruediger et al.

Part of American Journal of Hematology, p. 1214-1223, 2017

• DOI for First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY
• Download full text (pdf) of First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

Söderlund, Stina; Christiansson, Lisa; Persson, Inger; Hjorth-Hansen, Henrik et al.

Part of Leukemia Research, p. 95-103, 2016

• DOI for Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

Plasma Proteomics In Chronic Myeloid Leukemia Patients Before And After Initiation Of Tyrosine Kinase Inhibitor Therapy Reveals Induced Th1 Immunity And Loss Of Angiogenic Stimuli

Söderlund, Stina; Christiansson, Lisa; Persson, Inger; Hjorth-Hansen, H. et al.

Part of Haematologica, p. 730-730, 2016

Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia

Pfirrmann, M.; Baccarani, M.; Saussele, S.; Guilhot, J. et al.

Part of Leukemia, p. 48-56, 2016

• DOI for Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

Padula, William V.; Larson, Richard A.; Dusetzina, Stacie B.; Apperley, Jane F. et al.

Part of Journal of the National Cancer Institute, 2016

• DOI for Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States
• Download full text (pdf) of Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

Imatinib Discontinuation And Tki Switching Patterns In The Retrospective And Prospective Cohorts In Simplicity, A Study Of Chronic-Phase Chronic Myeloid Leukemia (Cp-Cml) Patients (Pts) In Routine Clinical Practice

Zyczynski, T.; Khoury, J.; Goldberg, S.; Mauro, M. et al.

Part of Value in Health, 2016

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

Hjorth-Hansen, Henrik; Stenke, Leif; Söderlund, Stina; Dreimane, Arta et al.

Part of European Journal of Haematology, p. 243-250, 2015

• DOI for Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
• Download full text (pdf) of Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

Hoffmann, V. S.; Baccarani, M.; Hasford, J.; Lindoerfer, D. et al.

Part of Leukemia, p. 1336-1343, 2015

• DOI for The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

ANALYSIS OF TREATMENT AND OUTCOME DATA OF 2904 PATIENTS FROM THE EUTOS POPULATION-BASED REGISTRY

Hoffmann, V. S.; Baccarani, M.; Hasford, J.; Lindoerfer, D. et al.

Part of Haematologica, p. 181-181, 2015

CARDIOVASCULAR (CV)-RELATED HOSPITALIZATION IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN SIMPLICITY, A PROSPECTIVE OBSERVATIONAL STUDY

Paquette, R.; Mauro, M.; Simonsson, Bengt; Abruzzese, E. et al.

Part of Haematologica, p. 437-437, 2015

The EUTOS Survival Score Is Preferable over the Sokal Score for Prognosis of Long-Term Survival of Patients with Chronic Myeloid Leukemia

Pfirrmann, Markus; Hasford, Joerg; Saussele, Susanne; Turkina, Anna et al.

Part of Blood, 2015

Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry

Hoffmann, Verena Sophia; Baccarani, Michele; Hasford, Joerg; Lindoerfer, Doris et al.

Part of Blood, 2015

The use of multiplex platforms for absolute and relative protein quantification of clinical material

Christiansson, Lisa; Mustjoki, Satu; Simonsson, Bengt; Olsson-Strömberg, Ulla et al.

Part of EuPA Open Proteomics, p. 37-47, 2014

• DOI for The use of multiplex platforms for absolute and relative protein quantification of clinical material

The Eutos Population Based Registry - Incidences of CML Across Europe

Hoffmann, V.; Lindoerfer, D.; Thaler, J.; Labar, B. et al.

Part of Haematologica, p. 72-72, 2014

Overall Survival and Prognosis in 2190 Patients with First-Line Imatinib Treatment Considering Death Due to Chronic Myeloid Leukaemia as the Only Event

Pfirrmann, M.; Saussele, S.; Baccarani, M.; Guilhot, J. et al.

Part of Haematologica, p. 531-532, 2014

The Eutos Population-Based Registry: Evaluation of Baseline Characteristics and First Treatment Choices Of 2983 Newly Diagnosed Chronic Myeloid Leukemia (Cml) Patients from 20 European Countries

Lindoerfer, D.; Hoffmann, V. S.; Rosti, G.; Castagnetti, F. et al.

Part of Haematologica, p. 238-239, 2014

TYROSINE KINASE INHIBITOR (TKI) SWITCHING: EXPERIENCE FROM SIMPLICITY, A PROSPECTIVE OBSERVATIONAL STUDY OF CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS IN CLINICAL PRACTICE

Hehlmann, R.; Cortes, J.; Gambacorti-Passerini, C.; Goldberg, S. L. et al.

Part of Haematologica, p. 328-329, 2014

Imatinib and pegylated IFN-alpha 2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response

Koskenvesa, Perttu; Kreutzman, Anna; Rohon, Peter; Pihlman, Markus et al.

Part of European Journal of Haematology, p. 413-420, 2014

• DOI for Imatinib and pegylated IFN-alpha 2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response

Survival and Prognosis in Patients with First-Line Imatinib Treatment Under Particular Consideration of Death Due to Chronic Myeloid Leukemia

Pfirrmann, Markus; Saussele, Susanne; Baccarani, Michele; Guilhot, Joelle et al.

Part of Blood, 2014

Incidence of CML in Europe -- a Comparison of 19 European Countries with US SEER Data

Hoffmann, Verena S.; Lindoerfer, Doris; Thaler, Josef; Boris, Labar et al.

Part of Blood, 2014

Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials

Baccarani, Michele; Hoffmann, Verena Sophia; Rosti, Gianantonio; Castagnetti, Fausto et al.

Part of Blood, 2014

What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?

Larson, Richard A.; Conti, Rena; Padula, William V.; Apperley, Jane F. et al.

Part of Blood, 2014

Cytogenetic and Molecular Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in a Prospective Observational Study (SIMPLICITY)

Mauro, Michael; Gambacorti-Passerini, Carlo; Goldberg, Stuart L.; Cortes, Jorge E. et al.

Part of Blood, 2014

Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

Christiansson, Lisa; Söderlund, Stina; Svensson, Emma; Mustjoki, Satu et al.

Part of PLOS ONE, 2013

• DOI for Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
• Download full text (pdf) of Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Höglund, Martin; Sandin, Fredrik; Hellstrom, Karin; Bjoreman, Mats et al.

Part of Blood, p. 1284-1292, 2013

• DOI for Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

Mustjoki, S.; Richter, J.; Barbany, G.; Ehrencrona, H. et al.

Part of Leukemia, p. 1520-1526, 2013

• DOI for Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

Overall survival and prognosis in patients with chronic myeloid leukaemia allocated to first-line imatinib treatment - new results from the EUTOS "In-Study" registry

Pfirrmann, M.; Saussele, S.; Baccarani, M.; Guilhot, J. et al.

Part of Onkologie (Basel), p. 100-100, 2013

The EUTOS CML score aims to support clinical decision-making

Hoffmann, Verena; Baccarani, Michele; Hasford, Joerg; Guilhot, Joelle et al.

Part of Blood, p. 2966-2967, 2012

• DOI for The EUTOS CML score aims to support clinical decision-making

Medical registries represent vital patient interests and should not be dismantled by stricter regulation

Hansson, Mats G; Simonsson, Bengt; Feltelius, Nils; Forsberg, Joanna Stjernschantz et al.

Part of Cancer Epidemiology, p. 575-578, 2012

• DOI for Medical registries represent vital patient interests and should not be dismantled by stricter regulation

Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet

Guilhot, Joelle; Baccarani, Michele; Clark, Richard E.; Cervantes, Francisco et al.

Part of Blood, p. 5963-5971, 2012

• DOI for Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet

Parental Age, Family Size, and Offspring's Risk of Childhood and Adult Acute Leukemia

Larfors, Gunnar; Hallböök, Helene; Simonsson, Bengt

Part of Cancer Epidemiology, Biomarkers and Prevention, p. 1185-1190, 2012

• DOI for Parental Age, Family Size, and Offspring's Risk of Childhood and Adult Acute Leukemia

Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Simonsson, Bengt; Gedde-Dahl, Tobias; Markevarn, Berit; Remes, Kari et al.

Part of Blood, p. 3228-3235, 2011

• DOI for Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Both CD4(+) FoxP3(+) and CD4(+) FoxP3(-) T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro.

Lindqvist, Camilla; Christiansson, Lisa; Thörn, Ingrid; Mangsbo, Sara et al.

Part of Immunology, p. 296-306, 2011

• DOI for Both CD4(+) FoxP3(+) and CD4(+) FoxP3(-) T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro.

T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies

Lindqvist, Camilla A.; Christiansson, Lisa H.; Simonsson, Bengt; Enblad, Gunilla et al.

Part of Immunology, p. 371-376, 2010

• DOI for T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies

Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph plus ALL receiving dasatinib

Olsson-Strömberg, Ulla; Hermansson, Monica; Lundan, Tuija; Ohm, Anne-Charlotte et al.

Part of European Journal of Haematology, p. 399-404, 2010

• DOI for Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph plus ALL receiving dasatinib

A population based registry in chronic myeloid leukemia (CML), a network of registries covering "representative" areas or regions of Europe (< 10 millions people)

Schrotz-King, P.; Hasford, J.; Lindoerfer, D.; Piccolo, C. et al.

Part of Onkologie (Basel), p. 147-147, 2010

Second-Generation BCR-ABL Kinase Inhibitors in CML

Simonsson, Bengt; Porkka, Kimmo; Richter, Johan

Part of New England Journal of Medicine, p. 1673-1673, 2010

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

Baccarani, Michele; Rosti, Gianantonio; Castagnetti, Fausto; Haznedaroglu, Ibrahim et al.

Part of Blood, p. 4497-4504, 2009

• DOI for Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

Mustjoki, S.; Ekblom, M.; Arstila, T. P.; Dybedal, I. et al.

Part of Leukemia, p. 1398-1405, 2009

• DOI for Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia

Feldman, E. J.; Cortes, J.; DeAngelo, D. J.; Holyoake, T. et al.

Part of Leukemia, p. 1707-1711, 2008

• DOI for On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia

Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia

Gupta, Manu; Milani, Lili; Hermansson, Monica; Simonsson, Bengt et al.

Part of Biochemical and Biophysical Research Communications - BBRC, p. 848-851, 2008

• DOI for Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia

Gene expression analysis identifies a genetic signature potentially associated with response to alpha-IFN in chronic phase CML patients

Hagberg, Anette; Olsson-Strömberg, Ulla; Wickenberg-Bolin, Ulrika; Göransson, Hanna et al.

Part of Leukemia Research, p. 931-938, 2007

• DOI for Gene expression analysis identifies a genetic signature potentially associated with response to alpha-IFN in chronic phase CML patients

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

Ottmann, Oliver; Dombret, Hervé; Martinelli, Giovanni; Simonsson, Bengt et al.

Part of Blood, p. 2309-2315, 2007

• DOI for Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up

Simonsson, Bengt

Part of Annals of Oncology, 2007

• DOI for Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

Brune, Mats; Castaigne, Sylvie; Catalano, John; Gehlsen, Kurt et al.

Part of Blood, p. 88-96, 2006

• DOI for Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

Klinische Forschung im „European LeukemiaNet”

Saussele, S.; Adam, K.; Hochhaus, A.; Béné, M. C. et al.

Part of Deutsche Medizinische Wochenschrift, p. 2423-2426, 2006

• DOI for Klinische Forschung im „European LeukemiaNet”

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Druker, Brian J.; Guilhot, Francois; O'Brien, Stephen G.; Gathmann, Insa et al.

Part of New England Journal of Medicine, p. 2408-2417, 2006

• DOI for Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

Baccarani, Michele; Saglio, Giuseppe; Goldman, John; Hochhaus, Andreas et al.

Part of Blood, p. 1809-1820, 2006

• DOI for Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of chronic myelogenous leukemia (CML).

Simonsson, B; Kloke, O; Stahel, R A

Part of Ann Oncol, 2005

Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-up.

Simonsson, Bengt; Oberg, Gunnar; Bjoreman, Mats; Bjorkholm, Magnus et al.

Part of Acta Haematol, p. 155-62, 2005

Epidemiology of chronic myeloid leukaemia: an update

Höglund, Martin; Sandin, Fredrik; Simonsson, Bengt

Part of Annals of Hematology, 2015

• DOI for Epidemiology of chronic myeloid leukaemia: an update

European LeukemiaNet recommendations for the management of chronic myeloid leukemia

Baccarani, Michele; Deininger, Michael W.; Rosti, Gianantonio; Hochhaus, Andreas et al.

Part of Blood, p. 872-884, 2013

• DOI for European LeukemiaNet recommendations for the management of chronic myeloid leukemia

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

Baccarani, Michele; Cortes, Jorge; Pane, Fabrizio; Niederwieser, Dietger et al.

Part of Journal of Clinical Oncology, p. 6041-6051, 2009

• DOI for Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

Imatinib or dasatinib treatment of chronic myeloid leukemia reduces circulating myeloid-derived suppressor cells but increases their CD40 expression

Christiansson, Lisa; Söderlund, Stina; Hjorth-Hansen, Henrik; Höglund, Martin et al.